IMVT
Price:
$33.62
Market Cap:
$6.90B
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Establishe...[Read more]
Industry
Biotechnology
IPO Date
2019-06-21
Stock Exchange
NASDAQ
Ticker
IMVT
According to Immunovant, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.09. This represents a change of -21.36% compared to the average of 11.55 of the last 4 quarters.
The mean historical Current Ratio of Immunovant, Inc. over the last ten years is 9.40. The current 9.09 Current Ratio has changed 9.56% with respect to the historical average. Over the past ten years (40 quarters), IMVT's Current Ratio was at its highest in in the September 2020 quarter at 35.15. The Current Ratio was at its lowest in in the June 2018 quarter at 0.
Average
9.40
Median
9.34
Minimum
0.07
Maximum
21.79
Discovering the peaks and valleys of Immunovant, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.12%
Maximum Annual Current Ratio = 21.79
Minimum Annual Increase = -47.12%
Minimum Annual Current Ratio = 0.07
| Year | Current Ratio | Change |
|---|---|---|
| 2026 | 9.09 | -18.59% |
| 2025 | 11.16 | -18.51% |
| 2024 | 13.70 | 46.67% |
| 2023 | 9.34 | -18.95% |
| 2022 | 11.52 | -47.12% |
| 2021 | 21.79 | 206.00% |
| 2020 | 7.12 | 733.56% |
| 2019 | 0.85 | 1.12% |
The current Current Ratio of Immunovant, Inc. (IMVT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
11.32
5-year avg
10.96
10-year avg
9.40
Immunovant, Inc.’s Current Ratio is less than Crinetics Pharmaceuticals, Inc. (18.60), greater than Viking Therapeutics, Inc. (5.72), less than Kymera Therapeutics, Inc. (10.81), less than Akero Therapeutics, Inc. (15.83), less than NewAmsterdam Pharma Company N.V. (9.76), less than Praxis Precision Medicines, Inc. (15.88), less than Dyne Therapeutics, Inc. (19.92), greater than ACADIA Pharmaceuticals Inc. (3.59), greater than Ultragenyx Pharmaceutical Inc. (2.02), greater than Soleno Therapeutics, Inc. (5.62),
| Company | Current Ratio | Market cap |
|---|---|---|
| 18.60 | $3.63B | |
| 5.72 | $3.34B | |
| 10.81 | $7.09B | |
| 15.83 | $4.50B | |
| 9.76 | $3.55B | |
| 15.88 | $5.64B | |
| 19.92 | $3.01B | |
| 3.59 | $3.61B | |
| 2.02 | $2.40B | |
| 5.62 | $2.76B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunovant, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immunovant, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Immunovant, Inc.'s Current Ratio?
How is the Current Ratio calculated for Immunovant, Inc. (IMVT)?
What is the highest Current Ratio for Immunovant, Inc. (IMVT)?
What is the 3-year average Current Ratio for Immunovant, Inc. (IMVT)?
What is the 5-year average Current Ratio for Immunovant, Inc. (IMVT)?
How does the current Current Ratio for Immunovant, Inc. (IMVT) compare to its historical average?